Evidence map›Paper›PMID 26185366›Full record

ReviewWorld journal of gastroenterology2015

Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries.

María José Domper Arnal, Ángel Ferrández Arenas, Ángel Lanas Arbeloa

Registry-linked trialOpen access · hybridAbstract readEditorialReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05954702 (Supercharged TRAM Evaluation in Cervical Esophagogastroplasty After Esophagectomy), which is not on this map. Cited by 578 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
578citing papers in PubMed, 3 pooled it
32.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05954702 narecruitingnot on this mapstarted 2023, after this paper: background citation

Supercharged TRAM Evaluation in Cervical Esophagogastroplasty After Esophagectomy

TypeinterventionalSponsorInstituto do Cancer do Estado de São PauloRan2023 to 2026Enrolled60ConditionsEsophagus Cancer, Carcinoma EsophagusArmsSupercharged TRAM esophagectomy, Conventional Esophagectomy
3 · Its place in the literature

Who cites it

578 citing papers in PubMed, 3 syntheses or guidelines pooled it, 1,027 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

518 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

María José Domper ArnalMaría José Domper Arnal, Ángel Ferrández Arenas, Department of Gastroenterology, University Hospital LB, Aragon Health Research Institute, IIS Aragon, 50009 Zaragoza, Spain.
Ángel Ferrández ArenasMaría José Domper Arnal, Ángel Ferrández Arenas, Department of Gastroenterology, University Hospital LB, Aragon Health Research Institute, IIS Aragon, 50009 Zaragoza, Spain.
Ángel Lanas ArbeloaMaría José Domper Arnal, Ángel Ferrández Arenas, Department of Gastroenterology, University Hospital LB, Aragon Health Research Institute, IIS Aragon, 50009 Zaragoza, Spain.
Instituto de Investigación Sanitaria Aragón · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Esophageal cancer is one of the most unknown and deadliest cancers worldwide, mainly because of its extremely aggressive nature and poor survival rate. Esophageal cancer is the 6(th) leading cause of death from cancer and the 8(th) most common cancer in the world. The 5-year survival is around 15%-25%. There are clear differences between the risk factors of both histological types that affect their incidence and distribution worldwide. There are areas of high incidence of squamous cell carcinoma (some areas in China) that meet the requirements for cost-effectiveness of endoscopy for early diagnosis in the general population of those areas. In Europe and United States the predominant histologic subtype is adenocarcinoma. The role of early diagnosis of adenocarcinoma in Barrett's esophagus remains controversial. The differences in the therapeutic management of early esophageal carcinoma (high-grade dysplasia, T1a, T1b, N0) between different parts of the world may be explained by the number of cancers diagnosed at an early stage. In areas where the incidence is high (China and Japan among others) early diagnoses is more frequent and has led to the development of endoscopic techniques for definitive treatment that achieve very effective results with a minimum number of complications and preserving the functionality of the esophagus.

Indexed as

EsophagoscopyAdenocarcinomaCarcinoma, Squamous CellEarly Detection of CancerEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaEsophagectomyHumansIncidenceNeoplasm StagingPredictive Value of TestsRacial GroupsRisk FactorsTreatment OutcomeAdenocarcinomaBarrett’s oesophagusEarly stageEndoscopic mucosal resectionEndoscopic submucosal disectionEpidemiologyOesophageal cancerScreeningSquamous cell carcinoma

Identifiers

PMID26185366
PMCPMC4499337
OpenAlexW2395739137

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.